

1. [Drug price cut yielded Rs 2,772 crore benefit to public: Government](#) - Economic Times

The government's decision to reduce prices of drugs, including those of cancer, cardiovascular diseases, AIDs/HIV and diabetes, has benefited the public to the tune of some Rs 2,772 crore, the Lok Sabha was told today.

Out of a total of 680 under the National List of Essential Medicines (NLEM) under the scheduled category of DPCO, 2013, the National Pharmaceutical pricing Authority (NPPA) has already fixed the ceiling prices in respect of 530 medicines, Minister of State of Chemicals and Fertilizers Hansraj Gangaram Ahir said in a reply to a question in the Lok Sabha.

This includes 47 formulations for cancer, 53 for cardiovascular diseases, 20 for AIDs/HIV and 6 for diabetes, Ahir said.

In addition, maximum retail has been capped in respect of 106, non-scheduled medicines, under para 19, of the Drug Price Control Order (DPCO) 2013, the minister added.

2. **T K Arun:** [How to make Make in India](#) – Economic Times

Rising up the rungs of the World Bank's Ease of Doing Business Index is not the be-all and end-all of making India a manufacturing powerhouse, never mind the government's fixation on this ranking. Nor are the additional requirements limited finance, power, roads, labour laws and logistics.

There are two other key pre-requisites. One, India has to support innovation and the creation of intellectual property at multiple levels: of policy, import duty, financial outlays and legal support. Two, Indian entrepreneurs must show ambition to operate on global scales of quality and quantity.

3. [India's pharma sector pips global growth: report](#) – Mint

The global pharma industry is set to grow at an annual rate of 5% between 2015 and 2020 to cross \$1.3 trillion by 2020 while the Indian market is expected to grow over 15% annually in this period, according to a study by UBM India, the Indian arm of London-based media and events company.

The report says the global pharma market is currently estimated to be over \$1 trillion in value, of which the US accounts for over 40%, followed by the European Union and Japan.

1. [Drug price cut yielded Rs 2,772 crore benefit to public: Government](#) – Economic Times
2. [How to make Make in India](#) – Economic Times
3. [India's pharma sector pips global growth: report](#) – Mint
4. [Subsidised medicines scheme Jan Aushadhi turns a failure](#) – DNA
5. [Start-ups with IP can help India's innovation capacity: Dr Wali](#) – Hindustan Times
6. [Pfizer's Long War on Taxation](#) – New York Times

4. [Subsidised medicines scheme Jan Aushadhi turns a failure](#) – DNA

The central government scheme to make quality generic medicines available to poor at affordable prices has almost ended in a failure, with a parliamentary committee on Tuesday revealing that only Rs 16.86 crore out of the allocated Rs 75 crore were utilised in the last three years.

The panel said while Rs 30 crore was allocated at the budgetary expenditure stage for Jan Aushadhi scheme for 2014-15, the finance ministry reduced the amount to nil in its revised expenditure due to non-utilisation of funds.

5. [Start-ups with IP can help India's innovation capacity: Dr Wali](#) – Hindustan Times

Dr Anil Wali, managing director of the Foundation for Innovation and Technology Transfer (FITT) at IIT-Delhi, interacted with HT Education on the sidelines of Pfizer's collaboration with the foundation on healthcare innovation and expressed the desire to make this programme a successful venture to fuel indigenous innovations in the country.

6. [Pfizer's Long War on Taxation](#) – New York Times

Long before Pfizer conceived of merging with Allergan in a \$150 billion deal to rid itself of what its chief executive called an "an uncompetitive tax rate" in the United States, the company was deploying various tax avoidance strategies dating back to at least 1976.